Our website uses cookies to provide you with a better experience. By continuing to use site you are giving us permission to
do this. Please see our Privacy Policy to learn more about cookies and how you can tailor your preferences

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    Contact us

    MrMrsMsDr



    Collection and Use of Personal Information. *

    DeepDx® Prostate – RP

    Description

    DeepDx® Prostate – RP (Radical Prostatectomy) detects tumor areas on radical prostatectomy WSIs. Diagnostic information such as tumor classification and quantification are automatically determined, resulting in a Gleason Score and ISUP (International Society of Urological Pathology) grade group and tumor segmentations.

    Tested by Professionals

    In an external validation study, the algorithm achieved an overall high agreement with the reference standard created by the consensus of the two uropathologists, with quadratic weighted kappa of 0.79.

    It performed especially well at clinically meaningful thresholds in evaluating benign vs malignant (κ 0.927), and clinically low-risk (benign, GG 1-2) versus high-risk (GG 3-5) disease (κ 0.858).

    In another study, the algorithm achieved an IoU of 0.8 for cancer coverage.

    * All kappa results were measured at the patch level.

    Explore More